Four-time Founder, Murat Kalayoglu, unveils a bold new thesis: if the U.S. wants to out-innovate China, it must rebuild biotech entrepreneurship from scratch, starting with a new model of training.
Four-time founder Murat Kalayoglu opened his DC Startup and Tech Week talk with a point that landed quickly: if the U.S. wants to stay ahead of China in biotech, we need to rethink how we train founders—fundamentally, not superficially. The room hadn’t even settled before he made it clear that the U.S. model that once powered the genomics revolution has slowed, grown expensive, and ceded momentum to a competitor moving with far more speed and focus
China
For most investors and life-science insiders, this isn’t news. But the way Kalayoglu told it, the danger isn’t incremental. It’s existential.
Over 30 years in medicine, immunology, ophthalmology, entrepreneurship and company-building, he’s watched the U.S. biotech model drift into something like a parody of itself: massive raises, oversized teams, big-pharma-trained executives who spend instead of build, and startups that burn nine figures without generating a single Phase 2 data point.
He used a recent example to make the point sting: a company that raised more than $300 million… and never reached the moment where anyone could know if its drug actually worked. If American biotech once defined scrappiness, speed, and a willingness to fail-fast on the way to scale, the current model looks more like a slow-moving capital-consuming organism.
Meanwhile, China has been assembling a development pipeline designed for efficiency.
Clinical trials cost 30–40% less. Phase I and II timelines are shortened by months. Regulatory alignment has converged with global standards. And Big Pharma has noticed: the rate of licensing deals sourcing assets from China has climbed sharply, now representing more than a third of global big-pharma in-licensing activity. Why pay a billion dollars for a U.S. asset when a similarly validated asset costs a third of the price?
If that trend line holds, the center of biotech gravity shifts decisively east.
Kalayoglu didn’t present this as doom. Instead, he presented it as a turning point.
His thesis: the U.S. only wins by getting radically scrappy again.
Not with another federal moonshot. Not with more capital. Not with more MBAs. But with a return to the oldest innovation technology civilization has ever deployed:
Apprenticeship
Not the polished, corporate-rotation version. The historical kind: Edison learning in a telegraph office, Franklin experimenting in a print shop, and the Wright brothers building in a bike shop—people learning by doing, making, breaking things, and carrying real responsibility on small budgets.
Kalayoglu argues that America has forgotten how to create these kinds of founders. Our system is optimized for capital absorption, not capital efficiency. We produce “rockstar” academics, not entrepreneurial operators. And venture ecosystems built around billion-dollar exits have created CEOs who treat scarcity as a threat instead of an accelerant.
Meanwhile, the model of the future founder?
He thinks it looks a lot more like the tenacious, single-founder hardware entrepreneur who spoke before him. Someone who can MacGyver experiments, stretch cash, improvise strategy, navigate risk, tolerate chaos, and iterate while everyone says they will fail.
If those founders aren’t entering the pipeline naturally, he believes the U.S. needs to engineer the pipeline ourselves.
Enter: SOAR
SOAR—Seed, Optimize, Advance, Repeat—is his new venture studio. It isn’t a fund and it doesn’t function like a traditional incubator. It operates more like a forge, placing early-career physicians and scientists inside real companies to work as actual operators under proven founders.
The goal is to produce leaders who can move fluidly between science and execution. No oversized C-suites. No committees. No unnecessary layers. Just lean companies led by people who can compete with China on speed, cost, and ingenuity.
And he sees Greater Washington as the only region where this can take root. The region’s concentration of federal labs, research ecosystems, and investment networks gives it structural advantages. Just as important is what the region doesn’t have: a long roster of scrappy repeat founders. That void leaves space for a new playbook to emerge.
Kalayoglu is clear that SOAR isn’t the full solution. It’s a starting point, a reset, and a push toward the mindset that once defined American innovation.
His warning is direct: keep operating the way we’ve been operating, and China pulls ahead.
Shift back toward apprenticeship, efficiency, and disciplined company building, and the next generation of biotech giants can come from here.
For investors in the room, the message was sharp: the future of U.S. biotech depends less on who spends the most and more on who trains founders to use capital effectively.
And Kalayoglu is betting his next decade on making sure they’re trained here.
See Murat’s full BioBuzz Presentation below.
View the other talks from the life science track at DCSTW here.
